<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>9</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>09</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Clinical Study on Safety and Efficacy of Qinin® (Cantharidin Sodium) Injection Combined with Chemotherapy in Treating Patients with Gastric Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>4773</FirstPage>
			<LastPage>4776</LastPage>
			<ELocationID EIdType="pii">26929</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;br/&gt;&lt;b&gt;Objectives&lt;/b&gt;: To assess the efficacy, side effects, and the impact on quality of life with Qinin® (Cantharidinsodium) injection combined with chemotherapy for gastric cancer patients. &lt;br/&gt;&lt;b&gt;Method&lt;/b&gt;: A consecutive cohort of 70patients were divided into two groups: experimental group with cantharidin sodium injection combined withchemotherapy, while the control group received chemotherapy alone. After more than two courses of treatment,efficacy, quality of life and side effects were evaluated. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: The response rate of experimental group wasnot significantly different from that of the control group (P&gt;0.05), but differences were significant in clinicalbenefit response and KPS score. In addition, gastrointestinal reactions and the incidence of leukopenia werelower than in the control group (P&lt;0.05). &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: Qinin® (Cantharidin sodium) injection combined withchemotherapy enhances clinical benefit response, improving quality of life of gastric cancer patients and reducingside effects of chemotherapy. Thus Qinin® (Cantharidin sodium) injection deserves to be further investigatedin randomized control clinical trails.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Cantharides sodium injection</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Chemotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">gastric cancer treatment</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_26929_cb0f826ef1ba64a98b48513aeb885b73.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
